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Felix Wieland
Editor of FEBS Letters since 1994Felix Wieland credits his scientiﬁc success to his natural curi-
osity and to fruitful collaborations with friends in his research
ﬁeld. Since 1988, Felix has been a full professor at the Univer-
sity of Heidelberg. With a gleam in his eye and an obvious
enthusiasm for his job, Dr. Wieland sat down with us and
shared his perspectives on his research and his plans for the fu-
ture. In addition to his managing editor duties, Felix edits
manuscripts in the ﬁeld of molecular cell biology, in particular
vesicular biology and protein transport.
Two members of your family have won Nobel Prizes.
Yes, this is true. My grandfather Heinrich Wieland won a No-
bel Prize in 1927 for discovering the structure of bile acid
which, ironically, was eventually corrected after the crystal
structure was determined. Feodor Lynen, my uncle, won a No-
bel Prize in 1964 for his discovery of Acetyl-CoA and its met-
abolic pathways that, by the way, help to form cholesterol, the
precursor of Heinrich Wieland’s bile acid.
There were more scientists in your family.
My father was a scientist too, and so was my father’s older
brother, Theodor Wieland. He established the chemistry of
peptide synthesis that led to gaseous reaction by-products,
eliminating the need to purify the products.
Has this scientiﬁc heritage in ﬂuenced your career?
Well, in a general way it probably did, making me familiar
with how a scientist thinks and behaves. So the inﬂuence is
not so much in my chosen ﬁeld but in the approach, to give
a phenomenon no respect but seek to solve it.
What is your lab working on?
We are working on the mechanisms that allow a vesicle to
form from a membrane. Our chosen model is the COPI vesicle,
produced in the Golgi and serving in the early protein secre-
tory pathway. We have characterized most of the machinery
that is needed to form this vesicle and have proven this mech-
anism by our ability to create vesicles in a controlled, reconsti-
tuted system. This has also led us into the ﬁeld of lipidology.
More recently we have started research in molecular immunol-
ogy, where we are characterizing the components and mecha-
nisms underlying the ‘‘cross-priming’’ of exogenous antigens as
presented by the major histocompatibility complex, MHCI.
Canonically, in the endoplasmic reticulum (ER), the MHCI
is loaded with antigens that have entered the ER by the0014-5793/$30.00  2005 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2005.02.003so-called TAP transporter. Once loaded, the MHCI starts its
travel via the secretory pathway to the cell surface, and here
you see the convergence of my two topics: both involve the
secretory pathway.
Do you have a favourite paper?
If the best paper is one that has had the most impact, I choose
our 1999 Cell paper [1] where we reconstituted vesicle budding
with the minimum machinery. But actually, the paper I en-
joyed writing the most was an early one, my 1983 PNAS paper
[2]. We described for the ﬁrst time that bacteria were able to
synthesize glycoproteins, and in the process we also discovered
a novel type of N-glycosyl linkage. The work was done in a
short period of time, and the results were novel, unequivocal
and surprising.
Is this how you characterize good science?
Partly but good science can also be the intelligent interpreta-
tion of known data to create a novel insight. Well, this is my
deﬁnition. The statutes of the Nobel prize say that good sci-
ence has to have a positive impact on mankind, not that it need
be clever or original, but personally I appreciate it more if
something is really novel, convincing and elegant in a simple
way.
What are you reading right now?
I’m currently on volume three of Churchill’s memoirs. History
is an important mirror to judge how politics function in the
present and to show how mistakes are repeated.
Could you comment on the current debate surrounding Open Ac-
cess publishing?
The question of open access deals with who pays, the author or
reader. Personally, I do not understand the advantage of hav-
ing the author pay rather than the consumer. I fear that scien-
tiﬁc quality may be compromised because under this system
the more papers a journal prints, the more money it receives.
Much good can be accomplished with the current system.
For example, FEBS Letters is a society journal and its entire
proﬁt ﬂows back into the scientiﬁc community. In my opinion,
this current debate is a reaction to Elsevier’s domination in the
scientiﬁc publishing market. I don’t agree with this reaction,
because other strong scientiﬁc publishers currently thrive, such
as Nature Publishing Group, Blackwell Publishing and Wiley
Publishers, to name a few.
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